
Daridorexant shows promise in treating insomnia and reducing comorbid symptoms. The study investigates the effect of the dual orexin receptor antagonist, daridorexant 50 mg, in 66 patients with insomnia disorder. Significant improvements in insomnia severity, anxiety, depression, and suicidal ideation were observed over 3 months. The findings suggest that targeting insomnia with daridorexant can also help alleviate co-occurring mood and anxiety symptoms, supporting its potential as a treatment for improving overall mental health.
Like
Save
Share